Domperidone and long QT syndrome

Current Drug Safety

Volumn 5, Issue 3, 2010, Pages 257-262

  Rossi, Marco ^a   Giorgi, Giorgio ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b Tuscan Regional Centre of Pharmacovigilance   (Italy)

Author keywords

Domperidone adverse effects; Drug interactions; Long QT syndrome; Torsade de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; AMPHOTERICIN; ANTINEOPLASTIC AGENT; BEPRIDIL; BLEOMYCIN; CIMETIDINE; CISAPRIDE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DELAYED RECTIFIER POTASSIUM CHANNEL; DEXAMETHASONE; DOFETILIDE; DOMPERIDONE; DROPERIDOL; FLUCONAZOLE; GENTAMICIN; HALOPERIDOL; KETOCONAZOLE; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; POTASSIUM CHANNEL HERG; TERFENADINE; TIOGUANINE; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL; DOPAMINE RECEPTOR BLOCKING AGENT;

ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOTOXICITY; CARDIOVASCULAR RISK; CARDIOVERSION; CASE CONTROL STUDY; CASE STUDY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DATA BASE; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROESOPHAGEAL REFLUX; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IN VITRO STUDY; LIVER METASTASIS; LONG QT SYNDROME; LUNG SQUAMOUS CELL CARCINOMA; MEDLINE; MYELOID LEUKEMIA; NAUSEA; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OVARY CARCINOMA; POTASSIUM TRANSPORT; PRESCRIPTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SUDDEN DEATH; TORSADE DES POINTES; ADULT; ANIMAL; CHEMICALLY INDUCED; CHILD; DEATH, SUDDEN, CARDIAC; DRUG INTERACTION;

ADULT; ANIMALS; ARRHYTHMIAS, CARDIAC; CHILD; DEATH, SUDDEN, CARDIAC; DOMPERIDONE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 77954676703     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610791698334     Document Type: Article

References (57)

1. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952; 6(3): 378-88.
2. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long- QT syndrome. N Engl J Med 1992; 327(12): 846-52.
3. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval JAMA 2003; 289(16): 2120-7.
4. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348(19): 1866-74.
5. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use- dependence. Circulation 1996; 93: 407-11.
6. Roden DM. QT bumps: unrevealing the mechanisms. J Cardiovasc Electrophysiol 2001; 12: 1379-80.
7. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96(6): 1698-703.
8. th ed. New York: McGraw-Hill 2006; p. 986.
9. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004; 58(3): 277-87.
10. Petraglia F, De Leo V, Sardelli S, et al. Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol 1985; 19(5): 281-7.
11. Da Silva OP, Knoppert DC, Angelini MM, Forret PA. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ 2001; 164(1): 17-21.
12. Product information. Motilium (domperidone). Janssen-Cilag S.p.A. June 2009.
13. Glassman M, George D, Grill B. Gastroesophageal reflux in children. Clinical manifestations, diagnosis, and therapy. Gastroenterol Clin North Am 1995; 24(1): 71-98.
14. Domperidone and sudden death. Prescrire Int 2006; 15(86): 226.
15. Domperidone and sudden death. Cardiac rhythm disorders: QT interval prolongation. Prescrire Int 2008; 17(94): 67.
16. Djelouah I, Scott C. Domperidone: heart rate and rhythm disorders. Canadian Adverse Reaction Newsletter 2007; 17(1). Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v 17n1-eng.php#a2 [Accessed Jan 12, 2010].
17. Medicines Control Council. Interaction between ketoconazole and domperidone and the risk of QT prolongation - important safety information. S Afr Med J 2006; 96(7): 596.
18. US Food and Drug Administration. FDA warns against women using unapproved drug, domperidone, to increase milk production [FDA Talk Paper]. Rockville (Md): FDA; 2004 June 7. Available from: www.fda.gov/bbs/topics/ANSWERS/2004/ANS01292.html [Accessed Jan 12, 2010].
19. http://www.azcert.org/medical-pros/drug-lists/list-01.cfm?sort=Gen eric_name [Accessed Jan 12, 2010].
20. http://www.meddramsso.com/MSSOWeb/index.htm.[Accessed Jan 12, 2010].
21. Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102(16): 1883-5.
22. Claassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 2005; 74(1): 31-6.
23. Stork D, Timin EN, Berjukow S, et al.State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 2007; 151(8): 1368-76.
24. Hreiche R, Morissette P, Zakrzewski-Jakubiak H, Turgeon J. Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs. J Cardiovasc Pharmacol Ther 2009; 14(1): 28-37.
25. Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patient on high-dose domperidone. Lancet 1982; 1: 1019.
26. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1984; 289: 1579.
27. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J, Chacon R. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep 1986; 70: 545-6.
28. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26: 720-3.
29. Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006; 40(7-8): 1456-61.
30. Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984; 2(8415): 1336-7.
31. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 1985; 2: 385.
32. Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Cardiac arrest after treatment with intravenous domperidone. Hum Toxicol 1985; 4: 617-26.
33. Ratcliffe JM, Nobbs J, Campbell RW, Hunter AS, Pritchard-Jones K, Craft AW. Continuous ECG monitoring of children with cancer receiving domperidone. Pediatr Hematol Oncol 1986; 3(4): 343-6.
34. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26(19): 2007-12.
35. th Annual Meeting). Drug Saf 2008; 31 (10): 917.
36. Dear Health Care Professional Letter: Important information concerning the interaction of ketoconazole and domperidone and the risk of QT prolongation, Janssen-Cilag, November 2005.
37. Sawant P, Das HS, Desai N, Kalokhe S, Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India 2004; 52: 626-8.
38. Hennessy S, Leonard CE, Palumbo CM, Bilker WB, Newcomb C, Kimmel SE. Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiol Drug Saf 2008; 17(12): 1131-6.
39. Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A. Effect of domperidone on QT interval in neonates. J Pediatr 2008; 153(5): 663-6.
40. Günlemez A, Babao lu A, Arisoy AE, Türker G, Gökalp AS. Effect of domperidone on the QTc interval in premature infants. J Perinatol 2010; 30(1): 50-3.
41. Hegar B, Alatas S, Advani N, Firmansyah A, Vandenplas Y. Domperidone versus cisapride in the treatment of infant regurgitation and increased acid gastro-oesophageal reflux: a pilot study. Acta Paediatr 2009; 98(4): 750-5.
42. http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafety ofproducts/Medicines/Druganalysisprints/index.htm [Accessed Jan 21, 2010].
43. http://www.lareb.nl/bijwerkingen/zoekresultaten.asp [Accessed Jan 21, 2010].
44. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97(2): 204-10.
45. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
46. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6(1): 61-70.
47. http://medicine.iupui.edu/flockhart/table.htm [Accessed Jan 21, 2010].
48. Pfeil N, Uhlig U, Kostev K, et al. Antiemetic medications in children with presumed infectious gastroenteritis-pharmacoepidemiol- ogy in Europe and Northern America. J Pediatr 2008; 153(5): 659-62.
49. Naranjo CA, Busto U, Sellers EM, et al. A Method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
50. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI. Proarrhythmia associated with cisapride in children. Pediatrics 1998; 101(6): 1053-6.
51. Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59(6): 725-9.
52. http://www.agenziafarmaco.it/REGISTRAZIONE_FARMACO/sec tion196d.html?target=&area_tematica=REGISTRAZIONE_FARM ACOion_code=AIFA_RF_ATTUALITA&entity_id=111.118132. 1188910804190 [Accessed Jan 31, 2010].
53. Kannankeril PJ. Understanding drug-induced torsades de pointes: a genetic stance. Expert Opin Drug Saf 2008; 7(3): 231-9.
54. Quinn N, Parkes D, Jackson G, Upward J. Cardiotoxicity of domperidone. Lancet 1985; 2: 724.
55. Venning GR, Reyntjens A. Safety of domperidone. Lancet 1982; 1(8283): 1255.
56. Cameron HA, Reyntjens AJ, Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1985; 290: 160.
57. Love EM, Yin JA, Delamore IW. Cardiotoxicity of intravenous domperidone. Lancet 1985; 2(8456): 676.